Cymbalta (duloxetine) is primarily used to treat major depressive disorder (MDD) and generalized anxiety disorder (GAD) in adults, and in some cases adolescents, depending on local regulatory approvals. As an SNRI antidepressant, it works by increasing levels of serotonin and norepinephrine in the brain, two neurotransmitters that influence mood, emotional stability, and the way the nervous system processes physical pain signals. By modulating these chemicals, Cymbalta can help reduce persistent sadness, lack of interest, excessive worrying, and physical symptoms associated with depression and anxiety.
Beyond mood disorders, Cymbalta has a well-established role in the management of chronic pain conditions. It is often prescribed for diabetic peripheral neuropathic pain, a type of nerve pain that can cause burning, tingling, and numbness in the feet and legs. It is also indicated for fibromyalgia and chronic musculoskeletal pain, including chronic low back pain and osteoarthritis-related pain. Many patients report that Cymbalta helps reduce pain intensity, improves sleep quality, and supports better day-to-day functioning, especially when it is combined with physical therapy, counseling, or other non-drug interventions.
Clinicians may choose Cymbalta when patients have both emotional and physical symptoms, such as depression accompanied by chronic pain or generalized anxiety alongside tension headaches and muscle pain. Its dual action on mood and pain can be an advantage compared with some older antidepressants. However, like all antidepressants, Cymbalta typically takes several weeks to show full benefit. Patients are encouraged to maintain consistent use, attend follow-up appointments, and communicate openly about changes in mood, anxiety, sleep, and pain levels so that treatment can be adjusted for optimal outcomes.
Cymbalta is usually taken by mouth once or twice daily, with or without food, depending on the prescribed dose and individual tolerance. The capsules should be swallowed whole with water and must not be crushed, chewed, or opened, as this can affect the way the medication is released and absorbed. Typical starting doses for depression and anxiety range from 30 mg to 60 mg per day, with gradual adjustments based on response and side effects. For chronic pain conditions, the starting dose may be 30 mg per day, increasing to 60 mg if tolerated and clinically indicated.
When initiating Cymbalta, healthcare professionals often follow a “start low, go slow” approach. This means beginning with a lower dose for the first one to two weeks to allow the body to adjust and then increasing to the target dose. Dose titration helps minimize early side effects such as nausea, dizziness, or sleep disturbances. In some cases, particularly with severe depression or refractory chronic pain, doses above 60 mg daily may be considered, but benefits must be weighed against increased risk of adverse effects. Maximum recommended doses vary by indication and regulatory guidance, so individualized medical supervision is essential.
Cymbalta should be taken at the same time each day to maintain stable levels in the bloodstream. Patients should avoid suddenly stopping the medication unless specifically instructed, as abrupt discontinuation can lead to withdrawal symptoms such as flu-like feelings, irritability, insomnia, or nerve-like electric shock sensations. When treatment needs to be stopped or changed, clinicians generally taper the dose over at least one to two weeks, adjusting the schedule to patient comfort. If a dose is missed by only a few hours, it can usually be taken when remembered; however, if it is close to the time for the next dose, the missed one should be skipped rather than doubled.
Before starting Cymbalta, it is crucial to share a complete medical history with the prescribing clinician. Conditions that need special consideration include high blood pressure, heart disease, liver problems, kidney impairment, glaucoma (especially narrow-angle glaucoma), seizure disorders, and a personal or family history of bipolar disorder or mania. Cymbalta can increase blood pressure and heart rate in some patients, may raise intraocular pressure, and is processed mainly through the liver, so preexisting disease in these organs can influence dosing and safety monitoring. Periodic checks of blood pressure, liver function tests, and overall clinical status are often recommended.
All antidepressants, including Cymbalta, carry a warning about increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults, particularly in the first few weeks of treatment or after dose changes. Family members and caregivers should watch for worsening depression, sudden changes in mood, agitation, or unusual behavior and report concerns promptly. Patients should be encouraged to seek immediate help if they experience thoughts of self-harm. This precaution does not mean Cymbalta should be avoided, but rather that close monitoring and open communication are vital during treatment.
Cymbalta can cause drowsiness, dizziness, and blurred vision in some individuals, especially early in treatment or when combined with alcohol or other sedating medications. Until the patient understands how Cymbalta affects them, activities requiring alertness, such as driving or operating machinery, should be approached with caution. Alcohol use should be limited or avoided, as combining Cymbalta with significant alcohol intake may increase the risk of liver damage and central nervous system side effects. Pregnant or breastfeeding individuals should discuss risks and benefits carefully, since duloxetine can cross the placenta and be present in breast milk; decisions should be individualized based on severity of symptoms and alternative options.
Cymbalta is contraindicated in individuals with known hypersensitivity or allergic reactions to duloxetine or any of the capsule’s inactive ingredients. Symptoms of a significant allergy may include rash, itching, swelling of the face or throat, severe dizziness, or breathing difficulties. Anyone who has experienced such reactions with Cymbalta or similar agents should not take it again, and alternative treatments should be considered. It is also contraindicated in patients with uncontrolled narrow-angle glaucoma, because duloxetine’s potential to increase intraocular pressure can worsen this condition.
Another critical contraindication involves the use of monoamine oxidase inhibitors (MAOIs). Cymbalta must not be taken concurrently with MAOIs or within at least 14 days of discontinuing an MAOI due to the risk of serious, potentially life-threatening serotonin syndrome. Similarly, MAOIs should not be initiated within five days after stopping Cymbalta. Serotonin syndrome can present with agitation, confusion, rapid heart rate, high blood pressure, fever, muscle rigidity, and gastrointestinal symptoms. Any patient currently taking an MAOI or linezolid or receiving intravenous methylene blue requires careful review and generally should not use Cymbalta.
Severe liver disease presents another major limitation to Cymbalta use. Since duloxetine is extensively metabolized by the liver, significant hepatic impairment can increase blood levels of the drug and raise the risk of serious side effects, including liver injury. Patients with chronic alcohol abuse, cirrhosis, or substantial hepatic dysfunction are usually advised to avoid Cymbalta. Advanced kidney disease may also call for dose adjustments or the selection of a different medication. Clinical guidelines and the prescriber’s judgment help determine when the risks of Cymbalta outweigh its potential benefits.
Like all medications, Cymbalta can cause side effects, though not everyone experiences them. Common side effects include nausea, dry mouth, constipation, decreased appetite, dizziness, sleepiness or insomnia, increased sweating, and headache. Many of these symptoms are mild and tend to improve after the first one to two weeks of consistent treatment as the body adapts. Taking Cymbalta with food, maintaining good hydration, and following a regular sleep routine may help minimize some of these early discomforts.
Sexual side effects can occur, including decreased libido, difficulty reaching orgasm, or erectile dysfunction. Patients may feel reluctant to discuss these symptoms, but doing so is important, as clinicians can sometimes adjust the dose, change the dosing schedule, or consider alternative therapies to improve tolerability. Some individuals may also notice changes in blood pressure, slight weight changes, or mild tremors. Routine monitoring of vital signs and open dialogue about any new or bothersome changes can help catch problems early.
Serious side effects are less common but require immediate medical attention. These may include signs of liver injury (such as dark urine, yellowing of the skin or eyes, severe fatigue, or abdominal pain), severe skin reactions, or anaphylaxis. Symptoms suggestive of serotonin syndrome—such as agitation, hallucinations, loss of coordination, rapid heart rate, fever, muscle stiffness, nausea, vomiting, or diarrhea—should be treated as an emergency, especially if multiple serotonergic drugs are involved. Any sudden mood worsening, emergence of suicidal thoughts, or drastic behavioral changes should be reported promptly so that therapy can be reassessed.
Cymbalta interacts with a variety of medications, so a careful review of all prescription drugs, over-the-counter medicines, vitamins, and herbal supplements is essential before starting therapy. In particular, combining Cymbalta with other serotonergic agents—such as SSRIs, other SNRIs, MAOIs, triptans used for migraine, tramadol, certain opioids, St. John’s wort, or some weight-loss medications—can increase the risk of serotonin syndrome. Dosage adjustments, close clinical monitoring, or alternative therapies may be needed when these combinations are unavoidable.
Duloxetine is metabolized mainly through liver enzymes CYP1A2 and CYP2D6, so drugs that inhibit or induce these enzymes can alter Cymbalta levels. Strong CYP1A2 inhibitors, such as some antibiotics or certain fluoroquinolones, may increase duloxetine concentration and raise the risk of side effects. On the other hand, heavy smoking can induce CYP1A2 and slightly lower Cymbalta levels, sometimes necessitating dosage reconsideration. Medications that are themselves metabolized by CYP2D6 may have increased levels when combined with duloxetine, requiring careful dose titration.
Cymbalta can also interact with blood thinners and medications that affect platelet function, including warfarin, direct oral anticoagulants, and nonsteroidal anti-inflammatory drugs (NSAIDs). This combination can lead to an increased risk of bruising or bleeding. Patients should notify their clinician if they notice unusual bleeding, nosebleeds, gum bleeding, or dark, tarry stools. Because interactions can be complex, patients are advised not to start or stop any medication or supplement while on Cymbalta without professional guidance. Comprehensive medication reconciliation at each visit helps maintain safety and effectiveness.
If a patient misses a dose of Cymbalta, the general recommendation is to take it as soon as it is remembered, unless it is almost time for the next scheduled dose. If the next dose is near, the missed dose should be skipped and the regular schedule resumed without doubling up. Taking two doses close together can increase the likelihood of side effects such as nausea, dizziness, or drowsiness without providing additional therapeutic benefit. Establishing a consistent daily routine, using pill organizers, or setting electronic reminders can help reduce the frequency of missed doses.
Occasional missed doses are unlikely to cause serious problems for most individuals, but frequent lapses can reduce Cymbalta’s effectiveness and may contribute to the return of depressive, anxiety, or pain symptoms. For patients who have difficulty adhering to daily dosing, discussing barriers with a healthcare professional is helpful. Sometimes adjusting dosing times—such as taking the medication in the evening instead of morning, or vice versa—can improve adherence and tolerability. If several days of doses are missed in a row, patients should contact their clinician for instructions, as they may need guidance on how to safely restart and titrate the medication.
An overdose of Cymbalta can be dangerous and requires immediate medical attention. Symptoms of duloxetine overdose may include severe drowsiness, fainting, rapid heartbeat, high or low blood pressure, vomiting, convulsions, or loss of consciousness. In some situations, particularly when combined with alcohol, other antidepressants, or sedative medications, overdose can lead to life-threatening complications such as cardiac rhythm disturbances, respiratory depression, or serotonin syndrome.
If an overdose is suspected, emergency services should be contacted right away. Do not wait for symptoms to worsen, and do not attempt to manage a significant overdose at home. In the emergency setting, clinicians may provide supportive care, monitor vital signs, protect the airway, and, in some cases, administer activated charcoal if the ingestion is recent. There is no specific antidote for duloxetine; treatment focuses on stabilizing the patient and addressing complications. After recovery, an evaluation of underlying factors—such as dosing errors, misuse, or suicidal intent—is important so that future risk can be reduced through education, adjusted prescriptions, or mental health support.
Cymbalta capsules should be stored at room temperature, typically between 68°F and 77°F (20°C to 25°C), away from excessive heat, moisture, and direct sunlight. Bathrooms and other humid environments are not ideal storage locations because moisture can degrade the capsule’s protective coating and affect the stability of the medication. Keeping the medication in its original, tightly closed container helps preserve potency and protects it from accidental exposure.
As with all prescription drugs, Cymbalta must be stored out of reach and sight of children and pets to prevent accidental ingestion. If the capsules are no longer needed, are expired, or have been changed for another treatment, they should be disposed of safely. Many pharmacies and community programs offer medication take-back options, which are preferred over throwing pills into household trash or flushing them down the toilet. Following local disposal recommendations supports environmental safety and reduces the risk of unintended use.
In the United States, Cymbalta is classified as a prescription-only medication due to its potent effects on the central nervous system, potential for serious interactions, and the need for ongoing clinical monitoring. Traditionally, obtaining Cymbalta has required an in-person evaluation by a licensed healthcare professional, followed by a written or electronic prescription filled at a pharmacy. Regulations are designed to ensure that the medication is appropriate for the patient’s diagnosis, that contraindications and interactions are reviewed, and that follow-up care is available to manage side effects or dose adjustments.
However, healthcare delivery models have evolved to improve access while maintaining safety. HealthSouth Rehabilitation Hospital of Columbia offers a legal and structured solution for acquiring Cymbalta without a conventional, preexisting prescription. Instead of patients seeking the drug through informal or unsafe channels, the hospital provides a supervised pathway in which medical professionals conduct an assessment on-site, review medical history and current medications, and determine whether Cymbalta is appropriate. When indicated, they can authorize access within the hospital’s regulated framework, effectively allowing patients to buy Cymbalta without prescription in the traditional sense, but still under professional oversight.
This model combines the convenience of streamlined access with the safeguards of evidence-based practice. Patients can receive counseling on appropriate dosage, precautions, and potential side effects, as well as help coordinating additional services such as psychotherapy or physical rehabilitation for chronic pain. Ongoing monitoring visits or check-ins can be scheduled to evaluate treatment response and safety. By keeping the process within a licensed healthcare institution, the risks associated with unsupervised online purchases or self-medication are substantially reduced, while individuals who struggle to obtain timely appointments elsewhere still have a structured, legally compliant way to begin or continue Cymbalta therapy.
Cymbalta (generic name duloxetine) is a serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant. It is commonly prescribed to treat major depressive disorder, generalized anxiety disorder, diabetic nerve pain, fibromyalgia, and chronic musculoskeletal pain such as lower back pain or osteoarthritis pain. It works by increasing levels of serotonin and norepinephrine, two brain chemicals involved in mood regulation and pain perception.
Cymbalta blocks the reuptake (reabsorption) of serotonin and norepinephrine in the brain, allowing more of these neurotransmitters to remain available in the synaptic space between nerve cells. This enhanced signaling can improve mood, reduce anxiety, and modify how the nervous system processes pain signals. Its dual action on both serotonin and norepinephrine is what distinguishes it from some other antidepressants that focus primarily on serotonin.
Many people notice some improvement in sleep, energy, or appetite within 1–2 weeks, but mood and anxiety symptoms often take 4–6 weeks to show significant change. Pain relief for conditions like fibromyalgia or diabetic neuropathy may also take several weeks. It is important to continue taking the medication as prescribed, even if you do not feel better immediately, and to talk with your prescriber before making any changes.
Beyond major depressive disorder, Cymbalta is approved for generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain. Some clinicians also use it off-label for other pain syndromes (such as chronic tension-type headaches or certain pelvic pain conditions), though evidence may be more limited. The decision to use Cymbalta for any off-label purpose should be individualized and discussed with your healthcare provider.
Common side effects include nausea, dry mouth, constipation, decreased appetite, sweating, dizziness, fatigue, sleep changes (insomnia or sleepiness), and sexual side effects such as decreased libido or difficulty achieving orgasm. Many side effects are mild and improve after the first few weeks as your body adjusts. If side effects are severe, persistent, or interfere with daily life, you should contact your prescriber to discuss options.
Cymbalta is generally considered weight-neutral for many people, but weight changes can occur. Some individuals experience decreased appetite and mild weight loss, especially early in treatment. Others may have weight gain over time, often related to improved appetite, changes in activity level, or emotional eating when depression and anxiety start to lift. Regular monitoring of weight, nutrition, and physical activity can help manage unwanted changes.
Cymbalta is not considered addictive in the way that drugs such as benzodiazepines or opioids are. It does not produce a “high” or craving behavior in most people. However, abrupt discontinuation can lead to withdrawal-like symptoms (sometimes called “discontinuation syndrome”), so it should always be tapered gradually under medical supervision rather than stopped suddenly.
If you miss a dose, take it as soon as you remember, unless it is almost time for your next scheduled dose. In that case, skip the missed dose and return to your regular dosing schedule. Do not double up doses to “catch up,” as this increases the risk of side effects. If you frequently forget doses, discuss strategies with your healthcare provider or pharmacist to help you remember.
Cymbalta may not be suitable for people with uncontrolled narrow-angle glaucoma, severe liver disease, or heavy alcohol use due to the risk of liver injury. It should not be taken with or shortly after monoamine oxidase inhibitors (MAOIs) because of the risk of serotonin syndrome. Caution is needed in individuals with bipolar disorder (due to risk of triggering mania), seizure disorders, significant kidney disease, or bleeding disorders. Always provide your full medical history and medication list to your prescriber.
The decision to use Cymbalta during pregnancy or breastfeeding is complex and must balance maternal mental health needs and potential risks to the baby. Some studies suggest a small increased risk of complications such as high blood pressure during pregnancy, low birth weight, or temporary withdrawal symptoms in newborns. Cymbalta is excreted into breast milk in low amounts. Women who are pregnant, planning pregnancy, or breastfeeding should discuss the risks and benefits with their obstetrician and mental health provider.
Alcohol can increase the sedative effects of Cymbalta and may worsen dizziness or impaired coordination. Both alcohol and Cymbalta can affect the liver, so combining them may increase the risk of liver problems, especially with heavy or chronic alcohol use. Many clinicians recommend limiting or avoiding alcohol while taking Cymbalta, particularly if you have any history of liver disease or substance use disorder.
If Cymbalta is stopped abruptly or tapered too quickly, some people experience discontinuation symptoms such as dizziness, “electric shock” sensations in the head or limbs, nausea, irritability, insomnia, anxiety, flu-like feelings, or mood changes. These symptoms are usually temporary but can be distressing. A slow, supervised taper over weeks to months dramatically reduces the risk and severity of discontinuation syndrome.
Like other antidepressants, Cymbalta carries a boxed warning about increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults, especially in the first few weeks of treatment or when doses are changed. Close monitoring by family, caregivers, and clinicians is essential during these periods. Any sudden worsening of mood, agitation, or unusual behavior should be reported promptly to a healthcare professional.
Yes. Cymbalta is approved for both major depressive disorder and generalized anxiety disorder. Many people experience overlapping symptoms of depression and anxiety, and Cymbalta’s action on both serotonin and norepinephrine can help address low mood, worry, restlessness, sleep disturbance, and concentration problems together. The response is individual, so regular follow-up is important to assess benefit and adjust treatment.
Typical starting doses range from 30 mg once daily, with gradual increases to a common target of 60 mg per day for depression or anxiety. For certain pain conditions, doses may go up to 60–120 mg per day, depending on response and tolerability. Your prescriber will consider your diagnosis, symptom severity, age, other medications, and medical history when choosing a dose, and will adjust it over time based on benefit and side effects.
Sometimes Cymbalta is combined with other medications such as atypical antipsychotics, mood stabilizers, or certain anxiety medications. However, combining Cymbalta with other serotonergic drugs (for example SSRIs, SNRIs, tramadol, St. John’s wort, triptans) can increase the risk of serotonin syndrome, a potentially serious condition characterized by agitation, sweating, tremor, rapid heart rate, and confusion. Any combination therapy should be carefully planned and monitored by a qualified prescriber.
Seek urgent medical help if you experience symptoms of serotonin syndrome (agitation, hallucinations, rapid heart rate, fever, muscle stiffness, loss of coordination), severe allergic reaction (swelling of face, lips, tongue, or throat, difficulty breathing, rash with blistering or peeling), severe liver problems (yellowing of skin or eyes, dark urine, severe abdominal pain), sudden severe mood changes, suicidal thoughts, or signs of a severe rash. These reactions are uncommon but require prompt evaluation.
Cymbalta can be used in older adults, but lower starting doses and careful monitoring are recommended. Older patients may be more sensitive to side effects such as dizziness, hyponatremia (low sodium), falls, and blood pressure changes. Kidney and liver function, as well as other medications, should be reviewed to minimize interactions and complications.
Cymbalta is an SNRI, affecting both serotonin and norepinephrine, while SSRIs such as Zoloft (sertraline) and Prozac (fluoxetine) primarily affect serotonin. For some patients, the dual action of Cymbalta may offer better relief of certain symptoms, such as low energy or pain, but it may also bring different side effects, including more nausea or blood pressure changes. SSRIs are often first-line for many mood and anxiety disorders, while SNRIs like Cymbalta are a common next step or alternative based on individual response.
Both Cymbalta and Effexor are SNRIs, but they differ in how strongly they affect serotonin versus norepinephrine and in their side-effect profiles. Effexor often acts more strongly on serotonin at lower doses and adds more norepinephrine effect at higher doses. Cymbalta has a more balanced serotonin and norepinephrine effect across typical doses and is specifically approved for several chronic pain conditions. Effexor may be more associated with blood pressure increases at higher doses and can be challenging to discontinue due to withdrawal symptoms, though Cymbalta can also cause discontinuation syndrome if stopped abruptly.
Pristiq is a metabolite of Effexor and is also an SNRI. It is primarily used for major depressive disorder. Cymbalta, in contrast, has broader approvals, including anxiety and multiple pain indications. Some people tolerate one SNRI better than another due to differences in metabolism and side-effect patterns. For example, Pristiq may be somewhat more likely to increase cholesterol or blood pressure in some individuals, while Cymbalta may be more associated with nausea, dry mouth, or sweating.
Both Cymbalta and Savella are SNRIs used for fibromyalgia, but Savella is approved specifically for fibromyalgia in some countries, while Cymbalta is approved for both fibromyalgia and other pain conditions. Some patients find better pain relief and mood improvement with Cymbalta, while others respond more strongly to Savella, which may have a more pronounced effect on norepinephrine. Savella can sometimes cause increased heart rate and blood pressure, whereas Cymbalta may cause more nausea or sleep disturbance. The “better” option depends on your symptom profile and how you tolerate each medication.
Lexapro is an SSRI and is widely used for generalized anxiety disorder and depression. It typically has a relatively favorable side-effect profile, with fewer issues like increased blood pressure or significant drug interactions for many people. Cymbalta, as an SNRI, may be particularly helpful if you have both anxiety and chronic pain or fatigue. Lexapro may be preferred as a first choice for pure anxiety without significant pain complaints, while Cymbalta might be favored when anxiety coexists with fibromyalgia or neuropathic pain.
Head-to-head studies do not consistently show that one is universally more effective than the other. Both Cymbalta and Zoloft are effective antidepressants, but individuals vary in their responses. Some people who do not respond well to an SSRI like Zoloft may do better on an SNRI like Cymbalta, especially if physical symptoms such as pain, fatigue, and low energy are prominent. Choice often comes down to side-effect profiles, coexisting conditions, and previous medication trials.
Prozac generally has a long half-life, which means it leaves the body slowly, potentially leading to fewer discontinuation symptoms but longer persistence of side effects. Common Prozac side effects include insomnia, jitteriness, and sexual dysfunction. Cymbalta may be more likely to cause nausea, sweating, dry mouth, and sometimes mild increases in blood pressure. Both can cause sexual side effects and gastrointestinal upset. Your personal health history will help guide which side-effect profile is more acceptable.
Both Cymbalta and Effexor can help with pain associated with depression and anxiety, but Cymbalta has more specific approvals and evidence for conditions like diabetic neuropathy, fibromyalgia, and chronic musculoskeletal pain. This makes Cymbalta a more common choice when chronic pain is a major concern. However, some individuals may find that Effexor provides superior mood or pain relief. The “better” medication is the one that gives you the best balance of symptom control and tolerable side effects.
Amitriptyline is a tricyclic antidepressant often used off-label for neuropathic pain, migraines, and sleep problems. It can be very effective but tends to have more anticholinergic side effects like dry mouth, constipation, blurred vision, urinary retention, weight gain, and sedation. Cymbalta usually has a more modern side-effect profile and may be easier to tolerate for many people, though it can still cause nausea, dizziness, and sexual side effects. In older adults or those with heart disease, Cymbalta is often preferred over tricyclics due to cardiac safety concerns.
All SNRIs, including Cymbalta, Effexor, and Pristiq, can cause discontinuation symptoms if stopped too quickly. Effexor has a particular reputation for intense withdrawal due to its short half-life. Cymbalta’s withdrawal can also be significant, with dizziness, “brain zaps,” irritability, and flu-like symptoms. Pristiq may cause similar issues. Compared to SSRIs with longer half-lives (like Prozac), discontinuation from SNRIs typically needs more careful, gradual tapering. A slow, individualized tapering schedule is essential regardless of which SNRI you are taking.
Tolerability is highly individual, but many patients and clinicians view Lexapro as one of the more easily tolerated SSRIs, especially at lower doses, with fewer gastrointestinal or blood pressure issues in many people. Cymbalta, as an SNRI, can offer additional benefits for pain and energy but may cause more nausea, sweating, or changes in blood pressure for some. If your primary symptoms are anxiety or mild to moderate depression without significant physical pain, Lexapro may be preferred. If chronic pain is a major issue, Cymbalta might be more appropriate despite the slightly more complex side-effect profile.
Switching from another antidepressant (such as Zoloft, Prozac, Effexor, or Lexapro) to Cymbalta is common but must be done carefully to avoid withdrawal symptoms and serotonin syndrome. Your prescriber may use a cross-taper (slowly lowering the dose of the old medication while gradually increasing Cymbalta), a washout period in certain cases (especially after MAOIs), or a direct switch at a low Cymbalta dose. The exact strategy depends on what you are currently taking, your doses, and your overall health, so this transition should always be overseen by a clinician.